Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041220 | 0.85 | GAA (0.46) | CFTRSMN1; SMN2TP53NPSR1MAPT | |
| SCHEMBL15712666 | 0.83 | CYP2A6 (0.47) | CYP2A6SMN1; SMN2TP53NPSR1MAPT | |
| SCHEMBL3052938 | 0.82 | TP53 (0.48) | SMN1; SMN2TP53NPSR1MAPTNR4A2 | |
| SCHEMBL9051843 | 0.81 | TSHR (0.43) | SMN1; SMN2TP53NPSR1 | |
| SCHEMBL7552732 | 0.77 | GABRA1 (0.52) | CYP2A6NR4A2 | |
| SCHEMBL1924214 | 0.76 | SMN1; SMN2 (0.48) | CFTRCYP2A6SMN1; SMN2TP53NPSR1 | |
| SCHEMBL3410158 | 0.76 | GPR84 (0.53) | CYP2A6 | |
| SCHEMBL21362751 | 0.75 | ALDH1A1 (0.60) | SMN1; SMN2MAPTHTTNPC1ALDH1A1 | |
| SCHEMBL15348693 | 0.75 | PBRM1 (0.54) | CYP2A6NR4A2CLK1CDK5CDK5R1 | |
| SCHEMBL3554889 | 0.75 | NR4A2 (0.68) | CYP2A6NR4A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816328-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2010-01-07 | — | — | US | disclosed |
| EP-1679965-A4 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | RYBCZYNSKI PHILIP | 2009-04-23 | — | — | US | disclosed |
| US-7482330-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-27 | — | — | US | disclosed |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | Tanabe Pharma Corporation (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7094763-B2 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARACEUTICA, N.V. (BE) | 2006-08-22 | — | — | US | disclosed |
| EP-1679965-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012318-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004160-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | CFTR 1002/4885CYP2A6 1159/4885SMN1; SMN2 4012/4885 |
| US-20060229260-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | CFTR 1002/4885CYP2A6 1159/4885SMN1; SMN2 4012/4885 |
| US-20090105162-A1 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | UGCG, UGGT1, GCG | CFTR 1002/4885CYP2A6 1159/4885SMN1; SMN2 4012/4885 |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | CFTR 1002/4885CYP2A6 1159/4885SMN1; SMN2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.